TEST

Nordson Test & Inspection Unveils Next-Generation X-Ray Inspection System at Semicon China 2023

Retrieved on: 
Wednesday, May 31, 2023

Nordson TEST & INSPECTION today announced that it will unveil the new Quadra 7 Pro Manual X-Ray Inspection (MXI) system at SEMICON China, scheduled to take place June 29 - July 1, 2023 at the Shanghai New International Expo Center in booth E3014.

Key Points: 
  • Nordson TEST & INSPECTION today announced that it will unveil the new Quadra 7 Pro Manual X-Ray Inspection (MXI) system at SEMICON China, scheduled to take place June 29 - July 1, 2023 at the Shanghai New International Expo Center in booth E3014.
  • View the full release here: https://www.businesswire.com/news/home/20230531005639/en/
    Nordson TEST & INSPECTION's Quadra 7 Pro MXI (Photo: Business Wire)
    The Quadra 7 Pro MXI system provides superior 3D/2D manual inspection with higher resolution for back-end semiconductor applications.
  • The new, advanced Onyx® detector technology inside provides lower noise for superior image clarity and faster frame rates.
  • “We are excited to unveil our next-generation MXI system, powered by the latest generation QuadraNT4 tube and new Onyx detector,” said Perry Duffill, VP of Nordson TEST & INSPECTION.

Nordson Test & Inspection’s CyberOptics SQ3000™+ Receives 7th Award

Retrieved on: 
Monday, April 17, 2023

Nordson Test & Inspection today announced that it received a 2023 EM Innovation Award in the category of Inspection for the CyberOptics SQ3000™+ Multi-Function system for AOI, SPI and CMM.

Key Points: 
  • Nordson Test & Inspection today announced that it received a 2023 EM Innovation Award in the category of Inspection for the CyberOptics SQ3000™+ Multi-Function system for AOI, SPI and CMM.
  • The award was announced during a ceremony held on April 14th at productronica China at the New International Expo Centre (SNIEC) Shanghai.
  • The SQ3000+, an extension of the multi-award-winning SQ3000 platform deemed best-in-class, has won a total of seven awards since its introduction.
  • “We are thrilled to receive our 7th award for the SQ3000+ Multi-Function inspection and metrology system for excellence in innovation,” said Perry Duffill, Vice-President of TEST & INSPECTION at Nordson Corporation.

ALLEN MEDIA GROUP AND CONDÉ NAST PARTNER TO ADD BON APPÉTIT, ARCHITECTURAL DIGEST AND GQ TO THE LOCAL NOW FREE-STREAMING SERVICE

Retrieved on: 
Thursday, February 2, 2023

ATLANTA, Feb. 2, 2023 /PRNewswire/ -- Local Now – Allen Media Group's leading free-streaming service for local news and entertainment in America – is proud to announce the launch of three new Free Ad-Supported TV (FAST) channels in partnership with Condé Nast Entertainment – Condé Nast's award-winning global film and television production company and global digital network and studio, distributing entertainment in every format across all platforms. Local Now has added these three Condé Nast FAST channels to its lineup:Bon Appétit, Architectural Digest, and GQ.

Key Points: 
  • From the Architectural Digest portfolio are hit series such as OPEN DOOR and ON THE MARKET.
  • And the extensive lineup of GQ original series include 10 ESSENTIALS, THE BREAKDOWN, MY FIRST MILLION, and ICONIC CHARACTERS.
  • "Bon Appétit, Architectural Digest, and GQ are phenomenal global brands known for their engaging and excellent content.
  • We are thrilled to bring these Condé Nast FAST channels that house such rich and entertaining series to our Local Now viewers," said Byron Allen, Founder/Chairman/CEO of Allen Media Group.

Encoder Market worth $4.3 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, November 30, 2022

The growth of the market attributed to the growing adoption of industry 4.0 and rising need for high end automation across industries driving the encoder market.

Key Points: 
  • The growth of the market attributed to the growing adoption of industry 4.0 and rising need for high end automation across industries driving the encoder market.
  • The absolute encoder determines the unique position of the value at every point of rotation by generating distinctive bit configurations.
  • A magnetic encoder uses sensors to identify changes in magnetic fields from a rotating magnetized wheel and convert them into electrical signals.
  • Asia Pacific dominated the encoder market and is expected to hold the same position during the forecast period.

Encoder Market worth $4.3 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, November 30, 2022

The growth of the market attributed to the growing adoption of industry 4.0 and rising need for high end automation across industries driving the encoder market.

Key Points: 
  • The growth of the market attributed to the growing adoption of industry 4.0 and rising need for high end automation across industries driving the encoder market.
  • The absolute encoder determines the unique position of the value at every point of rotation by generating distinctive bit configurations.
  • A magnetic encoder uses sensors to identify changes in magnetic fields from a rotating magnetized wheel and convert them into electrical signals.
  • Asia Pacific dominated the encoder market and is expected to hold the same position during the forecast period.

Access Ready Reporter Covers Orrin Hatch's Finest Hour

Retrieved on: 
Thursday, May 26, 2022

The California Voters Choice Act modernizes elections by providing more convenience and flexibility to voters.

Key Points: 
  • The California Voters Choice Act modernizes elections by providing more convenience and flexibility to voters.
  • This election model -- which has been in Fresno County for at least four elections now -- allows voters to choose how, when, and where to cast their ballot.
  • The world's #1 online resource for current news and trends in adaptive technology.
  • Adaptive Technology often refers specifically to electronic and information technology access.

My Eyelab Opens New Stores in Birmingham Area

Retrieved on: 
Monday, May 2, 2022

BIRMINGHAM, Ala., May 2, 2022 /PRNewswire/ -- My Eyelab, a leading optical retailer offering accessible and affordable eye care and eyewear, will open its newest locations in Birmingham late May and late June, with another to follow later in 2022. Located at 1711 Montgomery Highway in the Riverchase area and 5413 Highway 280, Suite 103 at the Cahaba Market, the two stores opening mark My Eyelab's debut in Alabama.

Key Points: 
  • Located at 1711 Montgomery Highway in the Riverchase area and 5413 Highway 280, Suite 103 at the Cahaba Market, the two stores opening mark My Eyelab's debut in Alabama.
  • "Moving into the Birmingham area with these three new locations gives us a lot of opportunity for growth and to capitalize on the optical market here," says Attawala.
  • Under the leadership of founder and CEO Daniel Stanton, My Eyelab is a retail brand of Now Optics, which also includes Stanton Optical.
  • For convenience, the new My Eyelab stores around Birmingham accept both same day appointments and walk-ins for your eye exams and eyewear needs.

DGAP-News: Defence Therapeutics Inc.: DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA

Retrieved on: 
Wednesday, October 6, 2021

Defence Therapeutics Inc.: DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA

Key Points: 
  • Defence Therapeutics Inc.: DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA
    The issuer is solely responsible for the content of this announcement.
  • DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA
    Vancouver, BC, Canada, October 6th, 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is finalizing all required steps in preparation to a pre-IND meeting to initiate a phase I trial against melanoma using its DC cancer vaccine candidate AccuVAC-D002.
  • Amongst its lead products is AccuVAC-D002, a DC-based cancer vaccine engineered to treat melanoma.
  • With two DC cancer vaccines (AccuVAC-D001 and D002) undergoing manufacturing in clean rooms, Defence is most likely to initiate its Phase I trials in Q1/Q2 of 2022.